Existing investor Lilly Asia Ventures helped the genome editing technology developer push its overall funding past the $100m mark.

The Omron-backed disease prevention platform developer hiked its total debt and equity financing to $100m, King River Capital leading the series C.

Relx and Telus-backed TigerConnect has now raised $149m in equity and debt financing for its healthcare messaging and collaboration platform.

Corvus spinoff Angel has secured series A funding from investors including Tigermed, Betta Pharmaceuticals and Hisun Pharmaceuticals.

UC Investments has backed cancer cell therapy developer A2 Biotherapeutics, bringing the company's total funding to $136m.

Oncology therapy developer A2 Biotherapeutics raised $71.5m from investors including Hartford HealthCare Endowment to take its funding to $136m altogether.

Applied Ventures contributed to a $50m round that pushed the total raised by the silicon photonics technology producer to $225m.

Kidney disease-focused drug developer Walden was co-founded by faculty members of Rush University and Harvard University earlier this year.

Existing investors including Intel Capital contributed to the $93.9m first close of the micro-LED technology developer's series D round.

UCB Pharma co-led a series A round for the kidney disease-focused drug developer through its UCB Ventures vehicle.